These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10897630)

  • 1. [Clinical assessment of Uro-Vaxom in the treatment and prophylaxis of recurrent urinary tract infection in children: preliminary results].
    Goszczyk A; Bochniewska V; Jung A
    Pol Merkur Lekarski; 2000 Apr; 8(46):242-3. PubMed ID: 10897630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Usefulness of Uro-Vaxom in complex treatment of recurrent urinary tract infections in girls].
    Gołabek B; Nowakowska K; Słowik M; Paruszkiewicz G
    Pol Merkur Lekarski; 2002 Apr; 12(70):269-72. PubMed ID: 12089885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the effectiveness of Uro-Vaxom in recurrent urinary tract infections in children].
    Czerwionka-Szaflarska M; Pawłowska M
    Pediatr Pol; 1996 Jul; 71(7):599-604. PubMed ID: 8803463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of Uro-Vaxom in treatment of recurrent urinary tract infections in girls].
    Gołabek B; Nowakowska K; Słowik M; Paruszkiewicz G
    Pediatr Pol; 1995 Dec; 70(12):1053-7. PubMed ID: 8649945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Uro-Vaxom on sIgA level in urine in children with recurrent urinary tract infections.
    Czerwionka-Szaflarska M; Pawłowska M
    Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):195-7. PubMed ID: 8915526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uro-Vaxom® versus placebo for the prevention of recurrent symptomatic urinary tract infections in participants with chronic neurogenic bladder dysfunction: a randomised controlled feasibility study.
    Wade D; Cooper J; Derry F; Taylor J
    Trials; 2019 Apr; 20(1):223. PubMed ID: 30992071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial.
    Magasi P; Pánovics J; Illés A; Nagy M
    Eur Urol; 1994; 26(2):137-40. PubMed ID: 7957468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells.
    Schmidhammer S; Ramoner R; Höltl L; Bartsch G; Thurnher M; Zelle-Rieser C
    Urology; 2002 Sep; 60(3):521-6. PubMed ID: 12350510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of uro-vaxom in recurrent infectious-inflammatory diseases of the urogenital system].
    Kul'chavenia EV; Breusov AA
    Urologiia; 2011; (4):7-11. PubMed ID: 22066233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Uro-Vaxom--expert in own defence].
    Akush Ginekol (Sofiia); 2008; 47 Suppl 1():28-9. PubMed ID: 18935855
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group.
    Tammen H
    Br J Urol; 1990 Jan; 65(1):6-9. PubMed ID: 2178724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Study of Immunotherapy Treatment with Uro-Vaxom (OM-89®) for Prophylaxis of Recurrent Urinary Tract Infections.
    Brodie A; El-Taji O; Jour I; Foley C; Hanbury D
    Curr Urol; 2020 Oct; 14(3):130-134. PubMed ID: 33224005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Frequency of recurrence after 3 days of therapy of the first infection of the lower urinary tract segment in children].
    Horanský V; Barboricová A; Slepecká I
    Cesk Pediatr; 1988 Nov; 43(11):684-5. PubMed ID: 3208348
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of urinary tract infection with a single dose of Biseptol].
    Cervenová O; Dzúriková V
    Bratisl Lek Listy; 1988 May; 89(5):340-2. PubMed ID: 3260807
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies.
    Bauer HW; Rahlfs VW; Lauener PA; Blessmann GS
    Int J Antimicrob Agents; 2002 Jun; 19(6):451-6. PubMed ID: 12135831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cystitis treatment with immunoactive Escherichia coli fractions].
    Conrad S; Huland H
    Dtsch Med Wochenschr; 1997 Apr; 122(14):460. PubMed ID: 9138926
    [No Abstract]   [Full Text] [Related]  

  • 17. Review of published studies on single dose therapy of urinary tract infections.
    Bailey RR
    Infection; 1990; 18 Suppl 2():S53-6. PubMed ID: 2286461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89.
    Huber M; Krauter K; Winkelmann G; Bauer HW; Rahlfs VW; Lauener PA; Blessmann GS; Bessler WG
    Int J Immunopharmacol; 2000 Dec; 22(12):1103-11. PubMed ID: 11137617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of Broncho-Vaxom in prevention of recurrent upper respiratory tract infection in children].
    Zielnik-Jurkiewicz B; Jurkiewicz D; Stankiewicz W
    Pol Merkur Lekarski; 2005 Nov; 19(113):625-9. PubMed ID: 16498798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Importance of individual approach to the immunoprophylaxis of recurrent urogenital infection].
    Kul'chavenia EV; Breusov AA
    Urologiia; 2013; (6):24-6. PubMed ID: 24649759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.